WEP Clinical LTD (WEP), a specialist services company that works with drug developers to help patients and physicians gain early access to medicines when no other treatment options are available, has partnered with biopharmaceutical company Pharming Group N.V. (“Pharming” EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) to launch a Post-Approval Named Patient Program (PA-NPP) for leniolisib.
Joenja® (leniolisib) is FDA approved for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older. The PA-NPP has been designed to ensure that physicians in Europe and the rest of the world can request leniolisib on behalf of individual patients living with APDS in certain countries where leniolisib is not commercially available.
This PA-NPP is the second access program WEP has been awarded by Pharming. The WEP team has been running an Expanded Access Program for leniolisib since June 2022.
Jas Khera, Managing Director of WEP, said:
“We are very pleased to be working with Pharming to help make leniolisib available to patients living in countries where this important medicine is not yet approved. This extended partnership reinforces our companies’ commitment to providing broader treatment access for patients worldwide.”
For physicians who are interested in further information on the leniolisib (PA-NPP), please contact: email@example.com.
At WEP Clinical, we are With Every Patient, as we believe every patient should have access to treatment! With this as our guiding principle, we have created a market leading, solutions driven, healthcare services company that partners with drug developers to create broader treatment access solutions for patients worldwide. We take pride in the high-quality output and positive customer experience we create while delivering our services. We specialize in the following: Expanded Access and Post-Approval Named Patient Programs; Market Access Solutions; Home Nursing Services for Decentralized Clinical Trials; and Clinical Trial Sourcing. For more information, please visit www.wepclinical.com.
About Pharming Group
Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules, biologics, and gene therapies that are in early to late-stage development. Pharming is headquartered in Leiden, Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific.